These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 26985893)

  • 1. A RNA-DNA Hybrid Aptamer for Nanoparticle-Based Prostate Tumor Targeted Drug Delivery.
    Leach JC; Wang A; Ye K; Jin S
    Int J Mol Sci; 2016 Mar; 17(3):380. PubMed ID: 26985893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy.
    Wu X; Ding B; Gao J; Wang H; Fan W; Wang X; Zhang W; Wang X; Ye L; Zhang M; Ding X; Liu J; Zhu Q; Gao S
    Int J Nanomedicine; 2011; 6():1747-56. PubMed ID: 21980237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual-aptamer-based delivery vehicle of doxorubicin to both PSMA (+) and PSMA (-) prostate cancers.
    Min K; Jo H; Song K; Cho M; Chun YS; Jon S; Kim WJ; Ban C
    Biomaterials; 2011 Mar; 32(8):2124-32. PubMed ID: 21147500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ultrasound-mediated nanobubble destruction (UMND) facilitates the delivery of A10-3.2 aptamer targeted and siRNA-loaded cationic nanobubbles for therapy of prostate cancer.
    Wu M; Zhao H; Guo L; Wang Y; Song J; Zhao X; Li C; Hao L; Wang D; Tang J
    Drug Deliv; 2018 Nov; 25(1):226-240. PubMed ID: 29313393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer.
    Bagalkot V; Zhang L; Levy-Nissenbaum E; Jon S; Kantoff PW; Langer R; Farokhzad OC
    Nano Lett; 2007 Oct; 7(10):3065-70. PubMed ID: 17854227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced growth inhibition of prostate cancer in vitro and in vivo by a recombinant adenovirus-mediated dual-aptamer modified drug delivery system.
    Jing P; Cao S; Xiao S; Zhang X; Ke S; Ke F; Yu X; Wang L; Wang S; Luo Y; Zhong Z
    Cancer Lett; 2016 Dec; 383(2):230-242. PubMed ID: 27721020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting tumor vasculature with aptamer-functionalized doxorubicin-polylactide nanoconjugates for enhanced cancer therapy.
    Tang L; Tong R; Coyle VJ; Yin Q; Pondenis H; Borst LB; Cheng J; Fan TM
    ACS Nano; 2015 May; 9(5):5072-81. PubMed ID: 25938427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MRI Assessment of Prostate-Specific Membrane Antigen (PSMA) Targeting by a PSMA-Targeted Magnetic Nanoparticle: Potential for Image-Guided Therapy.
    Ngen EJ; Benham Azad B; Boinapally S; Lisok A; Brummet M; Jacob D; Pomper MG; Banerjee SR
    Mol Pharm; 2019 May; 16(5):2060-2068. PubMed ID: 30912947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RNA aptamer-conjugated liposome as an efficient anticancer drug delivery vehicle targeting cancer cells in vivo.
    Baek SE; Lee KH; Park YS; Oh DK; Oh S; Kim KS; Kim DE
    J Control Release; 2014 Dec; 196():234-42. PubMed ID: 25450401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis of prostate cancer using anti-PSMA aptamer A10-3.2-oriented lipid nanobubbles.
    Fan X; Guo Y; Wang L; Xiong X; Zhu L; Fang K
    Int J Nanomedicine; 2016; 11():3939-50. PubMed ID: 27574424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A drug-loaded aptamer-gold nanoparticle bioconjugate for combined CT imaging and therapy of prostate cancer.
    Kim D; Jeong YY; Jon S
    ACS Nano; 2010 Jul; 4(7):3689-96. PubMed ID: 20550178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paclitaxel-loaded and A10-3.2 aptamer-targeted poly(lactide-
    Wu M; Wang Y; Wang Y; Zhang M; Luo Y; Tang J; Wang Z; Wang D; Hao L; Wang Z
    Int J Nanomedicine; 2017; 12():5313-5330. PubMed ID: 28794625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted chemoimmunotherapy using drug-loaded aptamer-dendrimer bioconjugates.
    Lee IH; An S; Yu MK; Kwon HK; Im SH; Jon S
    J Control Release; 2011 Nov; 155(3):435-41. PubMed ID: 21641946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells.
    Farokhzad OC; Jon S; Khademhosseini A; Tran TN; Lavan DA; Langer R
    Cancer Res; 2004 Nov; 64(21):7668-72. PubMed ID: 15520166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and biological evaluation of Doxorubicin-containing conjugate targeting PSMA.
    Ivanenkov YA; Machulkin AE; Garanina AS; Skvortsov DA; Uspenskaya AA; Deyneka EV; Trofimenko AV; Beloglazkina EK; Zyk NV; Koteliansky VE; Bezrukov DS; Aladinskaya AV; Vorobyeva NS; Puchinina MM; Riabykh GK; Sofronova AA; Malyshev AS; Majouga AG
    Bioorg Med Chem Lett; 2019 May; 29(10):1246-1255. PubMed ID: 30904185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epithelial cell adhesion molecule aptamer conjugated PEG-PLGA nanopolymersomes for targeted delivery of doxorubicin to human breast adenocarcinoma cell line in vitro.
    Alibolandi M; Ramezani M; Sadeghi F; Abnous K; Hadizadeh F
    Int J Pharm; 2015 Feb; 479(1):241-51. PubMed ID: 25529433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A ROS-responsive polymeric prodrug nanosystem with self-amplified drug release for PSMA (-) prostate cancer specific therapy.
    Wang Y; Zhang Y; Ru Z; Song W; Chen L; Ma H; Sun L
    J Nanobiotechnology; 2019 Aug; 17(1):91. PubMed ID: 31451114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study on the prostate cancer-targeting mechanism of aptamer-modified nanoparticles and their potential anticancer effect in vivo.
    Wu X; Tai Z; Zhu Q; Fan W; Ding B; Zhang W; Zhang L; Yao C; Wang X; Ding X; Li Q; Li X; Liu G; Liu J; Gao S
    Int J Nanomedicine; 2014; 9():5431-40. PubMed ID: 25473281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formulation/preparation of functionalized nanoparticles for in vivo targeted drug delivery.
    Gu F; Langer R; Farokhzad OC
    Methods Mol Biol; 2009; 544():589-98. PubMed ID: 19488725
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.